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Advances  in  the  Biology  and  Treatment  of B-Cell  Chronic 
Lymphocytic  Leukemia 
By Susan O’Brien, Auro  del  Giglio, and Michael Keating 
Chronic  lymphocytic  leukemia  (CLL)  is  the most  common 
type of  leukemia in the western  hemisphere.  Diagnosis  and 
staging  of  CLL  are  usually  straightforward,  but predicting 
an individual  patient’s  prognosis  is still  a  challenge.  Cytoge- 
netic  abnormalities  provide  important  prognostic  informa- 
tion in CLL  and  may show  its molecular  heterogeneity.  A 
search  for  oncogene  abnormalities  continues,  although  no 
consistent defects have  been  identified. New agents  such 
as  fludarabine  produce  high  complete  remission  rates  and 
HRONIC  lymphocytic  leukemia  (CLL)  is  a  clonal 
expansion of B lymphocytes with a low proliferative 
index but prolonged cell survival. It  is the most common 
adult leukemia in the United States. Its incidence increases 
with age. 
Recent investigations have contributed towards the under- 
standing of  the disease biology  and have resulted in  im- 
portant therapeutic discoveries that will be discussed in this 
review. 
C 
BIOLOGY AND  MOLECULAR ASPECTS 
Cytogenetic  and  molecular studies.  Chromosomal ab- 
normalities occur in 56% to 65% of patients with CLL who 
have sufficient metaphases for analysis.’,’  An  extra chromo- 
some 12 and a breakpoint involving the long arm  of chromo- 
somes 14 (14q+)  or  13 (13q+) are frequent abnormalities 
present in  18%, 13%, and  10% of  patients, respectively.’ 
Structural aberrations involving the long arm  of chromosome 
11 occur in 3% of patients.’ An abnormal karyotype in CLL 
portends a worse progn~sis.”~  Specific chromosomal abnor- 
malities  and  multiple  abnormalities  are  associated  with 
worse prognoses. Among patients having only a single chro- 
mosomal abnormality, those with trisomy 12 have a worse 
prognosis. When all abnormalities (single and multiple) are 
considered, patients with abnormal chromosomal 14 have 
the worst survival rate and those with  13q+ abnormalities 
have the  best, although all survival rates are  shorter than 
those seen in patients with a normal karyotype. The median 
survival rate in the latter group is more than 15 years.’  Pa- 
tients with a low percentage of  abnormal metaphases have 
a longer survival rate than those with 100% abnormal meta- 
phases. 
The rate of clonal evolution in CLL is variable. In a longi- 
tudinal  follow-up study of  95 patients, minor changes in 
karyotype were noted in 15% and 15% showed clonal evolu- 
tion in only one sample.’  In another study, karyotypic evolu- 
tion was seen in 22 of 53 patients (42%), 12 (55%)  of whom 
had disease progression, whereas progression was seen in 
only of 5 of  31 (16%) with  stable karyotypes (P  < .01). 
Abnormalities occumng during clonal evolution were differ- 
ent  from  the common baseline  abnormalities; trisomy  12 
was  not  observed  as  a  secondary abnormality.6 Southern 
blot analyses of Ig gene rearrangements showed a multiband 
pattern in 22 of 38 patients (58%).’  Loss of the JH germline 
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have  generated  interest  in earlier treatment as  a  first  step 
in a  potential  cure.  Fludarabine  also  makes  autologous  bone 
marrow  transplant  feasible as a  consolidation  therapy.  Im- 
munologic  abnormalities  and  minimal  residual  disease  per- 
sist in most  patients  in  remission.  Combining  fludarabine 
with other  active  agents  and  devising  effective  postremis- 
sion  strategies  may  change the natural  history of  CLL. 
0  7995 by The American  Society  of Hematology. 
band  or a Cu  multiband pattern has been  associated with 
advanced stage disease.8 
The molecular mechanisms underlying chromosome 12 
abnormalities in CLL are unknown. Involvement of the ras 
gene has been postulated because of its location, but no ras 
gene mutations were found in 93 patients st~died.’~’~  Probes 
for chromosome 12, the most common cytogenetic abnor- 
mality in CLL, will facilitate rapid screening for trisomy 12 
by fluorescence in situ hybridization (FISH). This approach 
is sensitive, specific, and evaluates cells in interphase.”  It 
has been also used to detect minimal residual disease after 
fludarabine chemotherapy.” 
The 14q+ abnormality involves a breakpoint at 14q32 at 
the site of the Ig heavy chain gene. Translocations such as 
t(11;14)(q13;q32)  may  juxtapose  critical  genes to  the  Ig 
heavy chain gene.13 Candidate genes located on  llq13 in- 
clude BCL-  1, CD20, int-2, hst, sea, and prad-l.13”7  Rechavi 
et all8 reported no BCL-1 or BCL-2 rearrangements in 38 
cases of  B-CLL. Adachi et all9 noted a 10% incidence (3 of 
32) of  BCL-2 gene translocation to Ig  A  or  K  light chain 
genes.”  The  14q+  abnormality is frequent in  prolympho- 
cytic leukemia.w Translocation of the BCL-2 gene is infre- 
quent in CLL, but expression of  the gene at the RNA  and 
protein level is increased. Schena et aiz1  found BCL-2 mRNA 
expression in l1 of  11 cases of B-CLL clones, whereas no 
expression was seen  in  normal  CD5+ B cells. Mariano et 
a1”  found expression of BCL-2 mRNA  in  20 of 20 patients 
with B-CLL; in 16 of  these 20 patients, the level of expres- 
sion was higher than that of normal peripheral blood  mono- 
nuclear cells. Increased expression of BCL-2 protein [com- 
pared with a t( 14; 18)-bearing  lymphoma cell line] was found 
in  14 of  20 cases of  CLL (70%); these levels varied from 
1.7 to 25 times the levels seen in normal peripheral blood 
 lymphocyte^.'^ All 20 cases showed complete demethylation 
at the 5’ end of  both  copies of the BCL-2 gene, although 
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this hypomethylation did not correlate with the relative levels 
of  BCL-2 protein. In the above studies, no rearrangements 
of  the BCL-2  gene were found, suggesting that  alternate 
mechanisms are responsible for enhanced protein overex- 
pression. Overexpression of  BCL-2 leads to  inhibition of 
apoptosis and  prolonged  survival  of  hematopoietic cells. 
Thus, the increased protein levels seen in B-CLL cells may 
be a crucial part of  their malignant phenotype. Hanada et 
studied this phenomenon in 3 cases of  B-CLL with low, 
intermediate, or high levels of  BCL-2 protein. After 72 hours 
of incubation, the viability of  cells with  low  BCL-2 protein 
expression was  -30%,  versus 60%  to 80% of  cells with 
higher BCL-2 levels. A morphologic picture consistent with 
apoptosis was  noted  in the cells with  low  protein level. 
The retinoblastoma (Rb) gene is located on the long arm 
of chromosome 13. By Southern blot analysis, abnormalities 
of  Rb are infrequent in CLL, having been reported in  1 of 
88 patients in two st~dies.~~,~~  Oscier et aIz6  showed deletion 
of this gene in 3 of 7 patients with B-CLL and a translocation 
involving chromosome 13. A study  using  in  situ  hybridiza- 
tion  to  interphase nuclei demonstrated Rb gene deletion in 
1  1 of 35 cases (3  1  %) of B-CLL; only 4 (1  1  %) had abnormal- 
ities of chromosome 13 by  conventional cytogenetic analy- 
sk2' 
Rb deletions in CLL are usually hemizygous.2x  Recently, 
somatic-cell hybrids have  been  used  to  pinpoint the  13q 
breakpoint in CLL. Two groups have identified a high fre- 
quency of  deletions of  D13S25, a distinct locus separated 
from Rb by  530 kb.29,30  This deletion occurred with higher 
frequency than the loss of  Rb; in 5 of  9 cases the deletion 
was homozygous, suggesting the presence of  a new  tumor- 
suppressor gene. Abnormalities in the expression of  the Rb 
gene, including decreased RNA message and  both underex- 
pression and overexpression of  the protein when compared 
with normal peripheral blood, have been  reported."," 
Abnormalities of  other oncogenes and tumor-suppressor 
genes have  been  found in  occasional patients with  CLL; 
however, no characteristic pattern of abnormal gene expres- 
sion has emerged. Gaidano et alS3  reported mutations of p53 
in 6 of 40 (15%) cases of CLL and  in 3 of 7 patients (43%) 
with Richter's transformation. El Rouby et  found a simi- 
lar  incidence of  p53 mutations in  CLL (8 of  53  [l5%]). 
Twenty-seven of  twenty-nine patients  (93%) without p53 
abnormalities responded to  treatment, versus only  1  of  7 
patients (14%) with  p53  abnormalities. 
Abts et a135  described expression of the proto-oncogenes 
lck and c-fgr in lymphocytes from 21 of  21 patients (100%) 
with CLL, but found no such expression in  normal  purified 
B cells. c-fgr and lck belong to the src gene family, which 
encodes tyrosine kinase proteins; their abnormal regulation 
may be relevant in the pathogenesis of  this disorder. 
Rearrangement of T-cell receptor genes have been occa- 
sionally reported in B-CLL. Merup et aP6  found T-cell recep- 
tor p gene rearrangement in 6 of  100 patients with B-CLL; 
3 of  the 6 patients had deletion of  the long arm of  chromo- 
some 6. An  additional patient had this abnormality in one 
metaphase; 6q  deletions were found in  only  4 of  the re- 
maining 94 patients.36. 
Zmmunophenotype.  Geisler et a137  have analyzed the im- 
munophenotype of  540 newly diagnosed patients with CLL. 
All cases showed CD19 andor CD20 (pan-B-cell antigens). 
CD5, an antigen present on mature T cells, was present in 
93%. Using a cut-off of  30%, positivity for CD21, CD22, 
and CD23 was  noted  in 65%, 86%, and 71%  of  patients. 
The presence of CD23 was strongly correlated with survival, 
with CD23- cases having a significantly shorter survival rate. 
Correspondingly, increased levels of  serum-soluble CD23 
confer a shorter survival rate in CLL patients."  In contrast, 
Newman et  a139 reported that patients with CLL and CD23 
positivity had a higher Rai stage and a higher white  blood 
cell count, suggesting more aggressive disease, but follow- 
up  was  too short to evaluate survival. CD23 regulation may 
have a regulatory role in B-cell proliferation:"  and studying 
the  mechanism of  its  abnormal expression is  of  interest. 
Myelomonocytic antigens are frequently expressed in CLL 
and have been associated with interleukin-l  (IL-l) produc- 
tion, a diffuse pattern of bone marrow infiltration, high levels 
of  C-FOS oncogene mRNA, and CD5 negativit~.~~.~"~' 
TREATMENT 
The diagnosis of CLL is not consonant with  the  decision to 
treat. Older age, a potentially indolent course, and  accepted 
incurability of the disease using conventional therapies make 
observation without treatment a tenable decision. Updated 
results from the French group CLL80 protocol corroborate 
this appr~ach.~'  Among stage A patients randomized to ob- 
servation versus daily chlorambucil, the 5-year survival rates 
were  82% versus 75% (P = .21). A delay in disease progres- 
sion in the treatment group was counterbalanced by a shorter 
survival once progression occurred and  by  a higher incidence 
of  epithelial cancers. Therefore, treatment for Binet stage A 
or  Rai stage 0 disease is indicated only  when progression or 
disease-related symptoms supervene. 
Response criteria.  The National Cancer Institute (NCI) 
and  the  IWCLL49*50  proposed  uniform  guidelines  for  re- 
sponse criteria (Table 1). A subset of patients with complete 
response (CR) may  have residual lymphoid nodules, which 
are sometimes seen  in  normal  marrow. Disappearance of the 
malignant clone by immunophenotypic parameters and gene 
rearrangement studies is  not  a requirement to  define  CR. 
Therefore, patients achieving CR may  be  heterogeneous, in- 
cluding hematologic and clonal CRs. Furthermore, the  im- 
pact of  achieving a clonal CR  on  the natural history  of  this 
disease is not clear.51  Robertson et  alS2  evaluated patients 
who achieved CR with fludarabine and prednisone therapy, 
based on whether CD5'  B cells were present in remission. 
For complete responders having no residual disease, the 2- 
year progression-free survival rate was 84%, compared with 
39%  in  patients having residual disease detected by  two- 
color now cytometry (P < .001).~~ 
Conventional treatment.  The most commonly used che- 
motherapeutic regimen in CLL is the combination of chlor- 
ambucil (CLB) and prednisone. The evidence supporting the 
use of  the combination instead of  either drug alone is based 
on two small, randomized studies in  which no  significant 
difference in survival was evident for the different treatment 
gro~ps.'~-~~  Responses with  this combination ranged  from 
38%  to  87%. This wide variation in response is a result of 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From ADVANCES  IN B-CELL  CLL  309 
Table 1. Response Criteria in CLL 
NCI  Criteria for Response in CLL‘’ 
Site  CR  PR 
Physical exam 
Nodes 
Liver/spleen 
Symptoms 
Peripheral blood 
PMN 
Platelets 
Hemoglobin 
(untransfused) 
Lymphocytes 
Bone marrow 
None 
Not palpable 
None 
~1,50O/pL 
>  100.000/pL 
>11.0  g/dL 
==4,OOO/pL 
40%  lymphocytes 
250% decrease 
250% decrease 
NA 
21,5OO/pL or >50% 
improvement  from 
baseline 
>lOO,OOO/pL  or >50% 
improvement  from 
baseline 
>11.0  g/dL  or  >50% 
improvement  from 
baseline 
250% decrease 
NA 
International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 
Response Criteriaso 
CR  Resolution of lymphadenopathy, 
hepatosplenomegaly, and constitutional 
symptoms. 
Neutrophils >1,5OO/pL 
Platelets >  lOO,OOO/pL 
Lymphocytes <4,OOO/pL 
Nodular or focal lymphoid infiltrates are 
compatible with CR 
PR  Change from stage C to A or B, or from stage 
B to A 
Normalization of CBC 
Normalization of bone marrow 
Stable disease  No change in the stage of the disease 
Abbreviations: PMN, polymorphonuclear cells; NA,  not applicable. 
several factors, including differences in response criteria and 
in drug dose schedules. The issue of dose intensity for chlor- 
ambucil is evident in the trial conducted by  Jaksic et al.56 
In  their study, 181 patients with CLL were randomized to 
treatment with continuous daily CLB (15 mg daily to CR or 
toxicity) or with weekly dose CLB (75 mg every week for 
6 weeks) plus prednisone. The total dose of  chlorambucil 
was  six times higher with the daily CLB regimen, which 
resulted in a CR rate of 70% compared with 31%  with  the 
weekly  schedule.  Survival  of  patients  randomized to  the 
high-dose regimen was also significantly superior. 
Several studies have investigated other drug combinations. 
COP (cyclophosphamide, vincristine, and prednisone) was 
associated with a response rate range of 44% to 82%,57-”  an 
outcome diversity accounted for by different patient charac- 
teristics, response criteria, and drug dose schedules. In  ran- 
domized trials, COP results were no bette?9,60  or inferior6’ 
to those obtained with CLB and prednisone. The addition of 
adriamycin to the COP regimen (CHOP) yielded superior 
survival results than COP  and higher response rates 
than  CLB plus prednis~ne.~,~~  A  recent update from  the 
French randomized study of CHOP versus CLB plus predni- 
sone for stage B CLL patients failed to show a significant 
survival difference between the two gro~ps.~  When CHOP 
was compared with high-dose CLB, no significant differ- 
ences  in  overall  response rates  were  seen between  regi- 
men~.~~  Other  combination  chemotherapy  regimens  have 
included M2 (vincristine, BCNU, cyclophosphamide, mel- 
phalan,  and  prednisone),68  CMP  (cyclophosphamide, 
melphalan,  and  predni~one),~~  CAP  (cyclophosphamide, 
adriamycin, and predni~one),~’  and  POACH (cyclophospha- 
mide,  adriamycin,  cytosine-arabinoside,  vincristine,  and 
predni~one).~’  Although these regimens induce higher CR 
rates, they  are more toxic and are not  clearly superior to 
CLB plus prednisone. 
Resistance to CLB in CLL is poorly  understood; alter- 
ations in  DNA  repair-synthesis activity and increased lev- 
els of  sulfhydryl groups, especially GST, have been pro- 
Resistance to other commonly used drugs in CLL 
(vinca alkaloids and anthracyclines) may be related to multi- 
drug resistance (mdr) gene expression. Several groups have 
reported increased levels of  mdr mRNA in a subset of  pa- 
tients with  CLL.76-80  The expression of mdr-associated glyco- 
protein in  some patients with  CLL has been reported by 
several  investigator^.^'.^^ Pharmacologic intervention to ame- 
liorate drug resistance mechanisms is of  interest. Elevated 
levels of topoisomerase-  1 found in  B-CLL lymphocytes sug- 
gest a role for the use  of  topoisomerase-l  targeting agents 
such as topotecan or CPT-11 in the treatment of  CLL.’l 
Nucleoside  analogues.  Nucleoside  analogues  have 
shown significant anti-CLL efficacy. Especially promising 
is fludarabine, a fluorinated purine analogue. Fludarabine is 
rapidly dephosphorylated in the plasma, enters the cell by a 
carrier-mediated transport mechanism, and is then phosphor- 
ylated to F-ara-adenine triphosphate (F-ara-ATP) by deoxy- 
cytidine kinase. Because of  its resistance to deamination by 
adenosine deaminase, F-ara-ATP accumulates in the  cell, 
leading to suppression of DNA synthesis by inhibiting ribo- 
nucleotide reductase and DNA polymerase  The signifi- 
cant activity of  fludarabine in lymphoid malignancies may 
be  related to  low  levels of  deoxynucleosides in lymphoid 
tissues and high deoxycytidine kinase activity. 
Grever et aIs3 administered fludarabine to 26 previously 
treated patients with CLL at a dose of 20 mg/m2 daily for 5 
days. Fourteen patients (54%) had clinical improvement and 
toxicity was  limited to myelosuppression. More than 300 
patients have received fludarabine-based chemotherapy at 
MD Anderson Cancer Centeraa7 since 1985. Keating et alW 
administered fludarabine intravenously at a dose of 25  to 30 
mg/m’  for 5 days every 3 to 4  weeks to 68 previously treated 
patients. Nine patients (13%) achieved a CR  and  30 (44%) 
achieved a partial response (PR), with  most of the responses 
occurring within 3 months of  treatment initiation. In  this 
initial study, PR  included responses in which the only evi- 
dence  of  disease  after  treatment  was  the  persistence  of 
lymphoid aggregates in the bone marrow. This was referred 
to as “nodular PR,”  but is recently called “nodular CR,” 
creating some confusion about the rates of response reported 
in  different series and  in  subsequent trials.  Patients with 
nodular CR belong to the CR category by IWCLL and  NCI 
criteria. Thus, CR rates in this study of  previously treated 
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Table 2.  Results of  Randomized  Trials  Comparing  Fludarabine 
to Combination  Chemotherapy 
Overall  Response Rate (%) 
~ 
Patients  No.  Fludarabine  CAP  CHOP 
(A)  Fludarabine v CAP 
All  208  58  42 
Pretreated  105  70  58 
Untreated  103  45  26 
(B)  Fludarabine  vCAP v CHOP 
Binet  stage  B  183  94  72  75 
Binet  stage C  79  64  84  62 
patients approached 30%  by  IWCLL/NCI guidelines. This 
led to a subsequent study with the same fludarabine regimen 
in 33 previously untreated patients.”  In this group, the CR 
and PR rates were 33% and 45%; considering patients who 
achieved a nodular CR, the CR rate increased to 72%. To 
enhance the single-agent activity of  this drug, prednisone 
was added at a dose of 30 mg/mZ  orally for 5 days in combi- 
nation with fludarabine administered at the same dose and 
schedule.86  Response rates did  not improve and 14 episodes 
of Listeria monocytogenes sepsis or pneumocystis carinii 
pneumonia (PCP) were observed among 269 patients (5%) 
treated. This occurrence is less than 1% of all courses admin- 
istered, but opportunistic infections had  not  been observed 
with fludarabine 
Toxicities observed with  fludarabine include myelosup- 
pression  and  infections. Complications are  more  frequent 
among nonresponding patients. Nausea, vomiting, stomatitis, 
diarrhea, and neurotoxicity, mainly  mild peripheral neuropa- 
thy, occur in less than 5% of  patients. Fludarabine does not 
cause alopecia. Encouraging results with fludarabine in CLL 
have  been  reported  by  other  although 
shorter-exposure  schedules  may  yield  lower  response 
 rate^.^.^' 
Puccio et a19’ used fludarabine 20 mg/m2 bolus followed 
by  30 mg/mz daily for 48 hours as  a continuous infusion. 
Response rates were inferior, but the total dose (80 mg/m2) 
and exposure duration were roughly half  that of  the daily 
for 5 days schedule (150 mg/m2).  Based on the slow elimina- 
tion of  FaraATP from CLL lymphocytes, fludarabine was 
administered at  30 mg/m’  weekly  to  47 previously treated 
patients with CLL. The dose was 80% of  that administered 
on a daily for 5 days schedule, but the overall response rate 
was  only  29%.”  A 3-day schedule of  fludarabine (30 mg/ 
m*  daily) in  80 patients with  relapsed or refractory CLL 
produced a response rate of  46%, which is not  significantly 
different from that reported with the 5-day schedule (unpub- 
lished data), but the incidence of CR was lower and detection 
of  residual disease (by  flow  cytometry) was more frequent 
with the shorter course therapy. 
Fludarabine has  been  approved  by  the Food  and Drug 
Administration for use  in  refractory CLL  and  is  now  in 
phase I11 trials being compared with  CLB  alone, CLB plus 
fludarabine, CAP, and CHOP (Table 2).  Hiddemann  et a19* 
presented preliminary data from a multicenter randomized 
triaI  comparing fludarabine with  CAP (750  mg/m2 cyclo- 
phosphamide, 50 mg/m2 adriamycin, and 40 mglm’  predni- 
sone X  5)  in patients with  CLL. The response rate in  106 
patients receiving fludarabine was 58%, versus 42% of  102 
patients treated with CAP. The response rate in previously 
treated patients was  45%  (21  of  53) with  Audarabine  and 
26%  (13 of  50) with CAP. Side-effects, including nausea, 
vomiting, and alopecia, were  more frequent with CAP. Binet 
et  al”  randomized 183 stage B and 79 stage C CLL patients 
to one of  three regimens:  25  mg/m’  fludarabine daily for 5 
days, CAP as described above, or mini-CHOP (300 mg/m’ 
cyclophosphamide and 40  mg/m2 prednisone orally  for  5 
days with  1 mg/m’  vincristine and 25 mg/m’  doxorubicin 
intravenously on  day  1). After 6 months, the response rate 
in  stage B patients was  94% with  fludarabine, 72% with 
CAP, and  75%  with  CHOP (P  = .08). There was  no signifi- 
cant difference in  response rates at  6 months for stage C 
patients, but  only  79 patients had  been  randomized. 
Two other purine analogues have  been  investigated. The 
Cancer and Leukemia Group B (CALGB) treated  CLL  pa- 
tients with pentostatin (2-deoxycoformycin [DCF]) at a dose 
of 4 mg/m2  intravenously weekly for 3 weeks and  then every 
2 weeks. One third of  the patients had  no  prior therapy  and 
69% were Binet stage C.94  Three percent  achieved a CR  and 
23% achieved a PR. Similar results were reported by  Ho et 
aLY5  Similar to the results with fludarabine, the most  common 
toxicities  were  infections  (52%)  and  myelosuppression. 
Other  significant toxicities included nausea  and  vomiting 
(31%), rash (20%), and stomatitis (8%). 
2-Chorodeoxyadenosine  (2-CDA)  was  investigated  in 
CLL at  0.2  to  0.5 mgkg/day  for 7 days as  a  continuous 
infusion and  yielded  a  PR  rate of  22%  in  18  previously 
treated  patientsy6 An  update of  the  study  showed a 44% 
response rate (4% CR and  40% PR) in 90 patients with  CLL 
using NCI criteria.” Although the CR  rate appears inferior 
to that of fludarabine, 82 of  the 90 patients treated had  Binet 
stage C disease and 8 of  8 patients with stage A or B disease 
responded. Documented infections were seen in 18% of  the 
patients, including three episodes of PCP and one episode 
of  Listeria. Thrombocytopenia to less than 50 X  10’/pL  was 
noted  in  25%  of  the patients. 
Twenty previously untreated patients received 2-CDA as 
a continuous infusion.98  The overall response rate was 85%, 
with CR being seen in 25%. The median  duration  of response 
is 8+ months. Three patients developed opportunistic infec- 
tions; all  had received steroid therapy for thrombocytopenia. 
The number of untreated patients receiving CDA is too small 
for significant comparison and imbalances in unaccounted 
prognostic factors may exist. Randomized studies comparing 
fludarabine with 2-CDA in CLL are needed, as well  as stud- 
ies using different dose schedules of  2-CDA. 
The three purine analogues share structural similarities, 
and  significant cross-resistance might  be  expected. Occa- 
sional patients resistant to fludarabine  have achieved a remis- 
sion  with  2-CDA. Juliusson et alW  treated four consecutive 
patients who  had  not achieved a PR with fludarabine and all 
responded to 2-CDA, with one patient achieving CR. Other 
groups have reported negative results in this setting. Delan- 
noy  et  allm saw  no responses in three fludarabine refractory 
patients treated  with  2-CDA. In a similarly treated group of 
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14 patients, Saven et all"  saw  no responses; treatment was 
complicated by  severe thrombocytopenia in 3 patients and 
pancytopenia  in  2  patients.  We  have  treated  28 patients 
whose disease was refractory to fludarabine with 2-CDA; 2 
patients (7%) responded by  NCI criteria and  1 additional 
patient  had  antitumor  activity  manifested  by  decreasing 
blood and marrow lymphocytosis, but persistent thrombocy- 
topenia.'"  Sixty-five percent of  courses were accompanied 
by febrile episodes or infections and 10  patients died within 
60 days of starting therapy with 2-CDA. The use of tandem 
nucleoside analogues may  result in cumulative myelosup- 
pression and immunosuppression with significant sequelae. 
Biologic response rnodt$ers.  a  Interferon induces a low 
response rate  in  previously treated patients.Io3  When  pre- 
viously untreated stage A CLL patients received a  interferon, 
about 50% achieved more than 50% reduction in their abso- 
lute lymphocyte  Investigation of  a interferon 
for remission maintenance (as for lymphoma and myeloma) 
is of  interest.'08,'w 
Trials of  a interferon in  combination with  other drugs 
such as chlorambucil and in high-risk stage A patients to 
decrease the rate of disease progression are underway."'*"' 
The mechanism of action of a  interferon in CLL is unknown. 
Downregulation of cytokines such as tumor necrosis factor 
(TNF) and activation of monocytes with elevation of macro- 
phage colony-stimulating factor (M-CSF) levels have been 
propo~ed."~*"~  Alternatively, the induction of leukocyte ad- 
hesion molecule-l  (LAM-l) on CLL cells by  a  interferon 
may alter the homing pattern of these cells and simply cause 
a compartment shift.'l4 
CLL B cells may produce mRNA for IL-10, transforming 
growth factor-0 (TGF-p), TNF-a, IL-6,  IL-7,  and  IL-~."~-"~ 
IL-1  and  IL-6  activity has  been  detected in  supernatants 
from cultured CLL cells. IL-4'20.121  and TGF-@22,123  have 
antiproliferative effects on CLL cells in vitro. Foa et  all" 
found circulating levels of  TNF in the serum of  20 of  24 
patients (83%) with CLL. This cellular release was higher 
in patients with  Rai  stage 0-1 disease than in patients with 
Rai stage 11-111 disease. Although in this study exogenous 
TNF had little proliferative effect on CLL cells, other investi- 
gators  have  found  significant  stimulation  by  TNF,125.126 
which may  be enhanced by  activation of  CLL  cell^.'^^"^' 
Moreover,  TNF induced  the  nuclear  transcription  factor 
NFKB and c-fos and c-jun mRNA in  B-CLL cells.131  The 
presence of circulation TNF receptors may stabilize TNF and 
increase the availability of this cyt~kine.'~,'~~.'~~  Inh ibition of 
TNF activity in  culture by  specific monoclonal antibodies 
corrected abnormal in vitro hematopoiesis in  11 of  15 CLL 
patients.'34  Thus, TNF may exert a regulatory role in CLL. 
The addition of  recombinant human IL-6 decreased TNF- 
induced growth of CLL cells in ~itro,'~~,'~~  in contrast to the 
growth stimulation effects of IL-6 on other B-cell neoplasms. 
When IL-6 levels were measured in the serum of 76 patients 
with  CLL,  detectable levels (>50 pg/mL)  were found in 
28%. Similar to the findings with TNF, the incidence of IL- 
6 detection was related to disease stage; 55% of Rai 0 pa- 
tients had IL-6 in the serum, versus 20% of Rai IV patients.lZ6 
Soluble  forms  of  TAC-reactive IL-2  receptors  are ex- 
pressed in  most patients with CLL and serum levels increase 
with advancing ~tage."~.'~~  Cell surface positivity is noted 
on the B-CLL cells in 50% of  cases. Kay et  investigated 
recombinant IL-2 at a dose of  2 X  lo6  U/m2 over 2 hours 5 
times per week in 12 patients with refractory or progressive 
CLL after chemotherapy; no partial or complete responses 
were observed, but 7 of  10 patients with evaluable disease 
had some evidence of tumor reduction and 3 had disease 
progre~sion.'~~  Using an IL-2 dose of  1.5  to  3 X  lo6 U/m2, 
Allison et  all3*  noted  decreases in  peripheral lymphocyte 
counts in 5 patients with CLL, but rebound to pretreatment 
levels upon  discontinuation of  the infusion. Toxicity was 
significant at the higher dose le~e1.I~' 
Hematopoietic colony-stimulating factors (CSF) such as 
granulocyte-CSF  (G-CSF)  and  granulocyte-macrophage- 
CSF (GM-CSF) may  ameliorate postchemotherapy or dis- 
ease-induced  ne~tropenia'~'  and  allow  administration  of 
higher doses of chemotherapy. Low-dose GM-CSF was OC- 
casionally superior to the conventional dose in  increasing 
neutrophil counts.'40 
Monoclonal antibodies and receptor-targeted irnrnunotox- 
ins.  Grossbard  et  all4'  recently  reported  results  from  a 
phase I study of  a monoclonal antibody toxin-conjugate di- 
rected at a B-cell-specific  antigen  (CD19) in  25 patients 
with refractory B-cell malignancies (mostly non-Hodgkin's 
lymphomas). By  blocking the nonspecific binding sites of 
ricin, a modified immunotoxin was engineered and then cou- 
pled to an  anti-CD19 monoclonal antibody. One CR, two 
PRs, and 8 minimal responses were observed. Toxicity con- 
sisted of  dose-dependent increases in transaminase levels, 
fever, hypoalbuminemia, and thrombocytopenia. The results 
obtained are encouraging and clinical testing of  this com- 
pound in CLL is underway. The use of  a hybrid molecule 
of  diphtheria toxin'42 or Pseudomonas toxin  with  the IL-2 
have also been reported in  CLL.  The search for 
more specific targets (ie, CD5 and CD23) and approaches 
tailored to circumvent the formation of  human  antibodies 
against the monoclonal antibodies (ie, humanization of  anti- 
bodies)'"  will probably extend the applications of this thera- 
peutic  modality, particularly in  the treatment of  minimal 
residual disease. 
Bone  marrow transplantation (BMT).  Experience with 
allogeneic BMT in patients younger than 50 years of age is 
slowly accumulating.'45t146  The combined international expe- 
rience was summarized for 47 CLL patients who received 
allogeneic transplants between 1984 and 1992.'47  Condition- 
ing usually consisted of  cyclophosphamide and total body 
irradiation (TBI); the most  common graft-versus-host dis- 
ease  (GVHD) prophylaxis  consisted of  methotrexate and 
cyclosporin. The median age was 42 years (range, 21 to 58 
years) and 56% of  patients were Rai stage 111-IV at the time 
of  BMT.  GVHD was  a significant problem and the most 
common cause of death post-BMT; 38% of patients experi- 
enced acute GVHD ?grade  I1 and  47%  had chronic GVHD 
(extensive in  17%). The projected leukemia-free survival 
was  40%  ? 18% at 5 years, with stage of disease being the 
most important factor influencing survival. 
Rabinowe et  treated 8 patients with CLL with a T- 
cell-depleted  allogeneic BMT using cytoxan and TB1 for 
conditioning. Patients were treated to a minor disease state 
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with  chemotherapy,  including  fludarabine  in  six  patients. 
Only  one  patient  had  severe  acute  GVHD  and  eventually 
died of PCP pneumonia.  With a median follow-up  of  1 1.7 
months,  six  patients  remain in CR  and  one patient has  bone 
marrow involvement  as  the  only  site of residual  disease. 
The  experience  at MD Anderson  is  similar to  that  of Rabi- 
nowe  et  al.'48 Eleven  patients  were  treated  with  allogeneic 
or  syngeneic  BMT  (l patient)  using  T-cell  depletion  and 
the  same preparative  regimen.  However,  all  patients  were 
refractory or relapsing  after  a  median of three  regimens  and 
nine  patients  were  staged  Rai  111-IV.  All  patients  had re- 
ceived  fludarabine.  Eight  patients  achieved  CR  and  one 
achieved PR. No patient  developed  GVHD  >grade  2;  one 
patient  developed  chronic  extensive  GVHD.  Ten  patients are 
alive with  a  median  follow-up  of  10 months.14'  In contrast 
to  the  European  experience,  the  incidence of severe  GVHD, 
with  consequent  early  death, is lower  in  the American  stud- 
ies.  All  but  two  patients  in the American  studies received 
therapy  with  fludarabine,  a  potent  immunosuppressive  agent, 
whereas  none  of  the  European  patients  was  treated  with 
this  drug.  T-cell  suppression, seen  with  fludarabine,  may 
interfere  with  antigen  presentation  to  the  donor  cells,  re- 
sulting  in  a decrease in the  incidence of  GVHD.  Because of 
age constraints  and  donor  availability,  only a  minority  of 
CLL patients  can  be  considered  for  allogeneic  BMT.  Its 
application in CLL is  investigational,  and patients  should  be 
treated  in  the  setting of  clinical  trials. 
Autologous  BMT  may  be an  alternative  investigational 
option  for  this older  group  of  patients.  Purged  autologous 
marrow has  been  used  as  consolidation  remission  in  low- 
grade  lymphoma,  an analogous  disease  entity.  Patients  ren- 
dered negative  for bcl-2 rearrangement at the  polymerase 
chain reaction  level  had  prolonged  disease-free survival."" 
Rabinowe  et al'"  used  monoclonal  antibody-purged  autolo- 
gous  bone  marrow to treat 12 patients with CLL, using cyclo- 
phosphamide  and  TB1  as  the  preparative  regimen.  As did 
the allogeneic BMT patients, all 12 achieved  a  minimal  dis- 
ease  state with chemotherapy  before  BMT.  One  patient  died 
with  pulmonary  hemorrhage  and  all  but  one of  the  other 
patients  remain  in  CR  with  a  median  follow-up  of  5 
months.'4x 
Khouri et allJ9  treated  l1 patients  with  CLL with  purged 
autologous BMT. AI1 patients  had relapsed  after  fludarabine 
therapy and the  median number of prior regimens  was  three. 
There  was  one  death  from  cytomegalovirus  infection  and 
one  death  from  complications  of  liver  biopsy;  3  patients 
remain  in  CR with  a  median  follow-up  of  10  months.'4y 
SPECIAL  PROBLEMS 
Autoimmune complications.  When present  in  CLL, auto- 
antibodies are preferentially  targeted  against  hematopoietic 
cells. The  incidence  of autoantibodies  in  CLL ranges  from 
10% to 75%; the incidence of  a  positive  Coombs test  in- 
creases significantly  with  disease  stage.'" 
The  approach  for  patients  with immune  thrombocytopenia 
or  autoimmune hemolytic  anemia  and  CLL  includes  an  ini- 
tial  trial  of  steroids  (prednisone,  60  to 100 mg/day)  for 2 
weeks.  Seventy-five  percent  of patients  will  respond,  and  an 
attempt to taper  the  steroid dose slowly  should  follow. For 
steroid  refractory  patients,  alternatives  include a  trial  of intra- 
venous Ig or a splenectomy. 
Pure red blood  cell  aplasia  characterized by severe  anemia, 
reticulocytopenia, and a marrow  with less  than 0.5% mature 
erythroblasts may occur in CLL in less  than  1% of patients. 
Cyclosporin has demonstrated activity  in this  setting,  even 
in  patients  resistant  to  conventional  immunosuppressive 
therapy.I5'  A  case of  bone  marrow  aplasia  associated  with 
CLL that responded  to  antithymocyte  globulin  has  been re- 
ported.I5' 
The  mechanism  of  the autoimmune manifestations of CLL 
is not  understood.  Two  groups  have  reported  that  fusion  of 
CLL  and  myeloma  cells yields  monospecific  and polyspe- 
cific autoantibodies."',15'  These polyspecific  autoantibodies 
are of the  IgM  class  and  exhibit  a  restricted  use  of highly 
conserved Ig  V   gene^.'^^.''^  The preferential  use  of  these 
highly  conserved V  genes  suggests  that  a  biased  selection 
of germinal Ig V gene repertoire,  rather  than somatic muta- 
tion, is responsible  for  the appearance of autoantibodies  in 
this disorder.'5h15X  Inghirami et al'"  has reported  a  naturally 
occurring CD5'  B-cell  subset  that  resembles the  autoanti- 
body  producing  B-CLL  cells.  In  both  situations,  there  is 
restricted  expression  of  Ig  V genes that raises the possibility 
that  B-CLL may  arise  from  this  normal  B-cell  subset  en- 
gaged in autoantibody  production.'57~lh'' 
Alternative  explanations  for  the  CLL  autoimmune  phe- 
nomena  have  been  proposed,  including increased  spontane- 
ous secretion of IL-6 by lymphocytes of CLL patients with 
autoimmune  disease  and  decreased  T-suppressor  inducer 
cells  (CD45RA).Ih'.'"' 
Transformation.  Richter's  transformation  occurs  in 
about  3%  to  10%  of CLL  cases  and  represents  a  change  to 
a  large-cell  lymphoma  (LCL)  histology.  Robertson  et  allh3 
reported  on  39 patients  with CLL  who  developed  LCL.  This 
represented 3% of the patients  enrolled  on  a  computer-based 
registry  at  MD Anderson  between  1972  and  1992.163  LCL 
was  found  in patients  in  all Rai stages  and  in  10 patients in 
CR after  fludarabine  therapy.  The incidence of  transforma- 
tion  after  fludarabine or 2-CDA therapy was not  significantly 
increased. Symptoms  at transformation  included  progressive 
lymphadenopathy and  systemic  symptoms in the  majority of 
patients.  Extranodal  involvement  and  paraproteinemia  were 
noted  in  41%  and  44%, respectively.  The  most  frequent 
clinical  feature  was  elevation  of  lactate  dehydrogenase 
(LDH), with 82% of patients evincing a  value  that  was  more 
than  twice  normal.  In contrast,  only  8%  of  CLL patients 
presenting  to  MD  Anderson  (treated  or  untreated)  had  this 
level of LDH elevation. As noted in other studies,  median 
survival was  short at 5 months, although  responders  to  che- 
motherapy  lived  longer than  nonresponders.Ih4 
It is  unclear  whether  the  LCL  cells  represent clonal  evolu- 
tion from B-CLL or the appearance of a  new  and  unrelated 
clone~'h'-lhY  The possibility  that  in some  cases  de novo LCL 
arises in a background of a CLL-induced  immunodeficiency 
cannot  be  ruled  out.  In the  study  by Robertson  et  al,'"  12 
of  15  patients  showed the same light  chain  isotype in both 
the  CLL  and  LCL  cells.  However, a  change may  simply 
represent  isotype switch.  Five patients  who  had  Southern 
blotting  performed on both types of cells  showed  an  identical 
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pattern of heavy- and light-chain rearrangement.  The  avail- 
ability of molecular  techniques  to  study  clonality  coupled 
with  the  recent  description  of  an  NZB  mouse  model  for 
CLLl7O  in  which  a  Richter-like transformation  has  been ob- 
served  may  elucidate  this question.  Prolymphocytoid  trans- 
lymphocytic  leukemia  (PLL).  Patients  with  prolymphocytoid 
transformation  have  an  indolent  progression  of  anemia, 
thrombocytopenia,  and  splenomegaly  associated  with an in- 
crease in  the  percentage of prolymphocytes  to 30% or  more 
of the leukemic cells. Unlike  de novo PLL,  the  immunophe- 
notype of the prolymphocytes  in  prolymphocytoid  transfor- 
mation is similar to the classic B-CLL cells, suggesting that, 
in  most  instances,  prolymphocytoid  transformation involves 
the  original  B-CLL  clone. 
CLL evolving into  acute  lymphocytic  leukemia  is a rare 
phenomenon,  occurring  in  less than  1% of cases, and  has 
not been  fully ~haracterized.'~~  Isolated cases of CLL  trans- 
formation  into  small  noncleaved  cell lymphoma,  lympho- 
blastic  lymphoma,  hairy  cell leukemia, and Hodgkin's  dis- 
ease have  been rep~rted.'~~"~~ 
formation171J72 1s  .  clinically  different  from  de  novo  pro- 
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